Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Human Immunodeficiency Virus (HIV)

Human Immunodeficiency Virus (HIV)

                        About HIV and the Center for Drug Evaluation and Research's role
          What's New at CDER in HIV/AIDS


                        HIV Treatment Home
          Drugs
          Drug Safety and Availability
          Information by Drug Class
          Human Immunodeficiency Virus (HIV)
          What's New at CDER in HIV/AIDSHuman Immunodeficiency Virus (HIV) What's New at CDER in HIV/AIDS
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintGet updates on safety and regulatory issues related to HIV/AIDS medical products such as:

product approvals
	significant warnings
	safety warnings
	notices of upcoming public meetings
	notices about proposed regulatory guidances

Clear Search
 

Date
			Subject3/11/2021
			The Food and Drug Administration approved revisions to the TRIUMEQ (abacavir/dolutegravir/lamivudine) and DOVATO (dolutegravir/lamivudine) labels1/26/2021
			FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection8/7/2020
			FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling to include a new indication and provide longer term safety and efficacy data8/4/2020
			FDA approved the product labeling for PREZCOBIX and EVOTAZ for use in pediatric patients1/29/2020
			PEPFAR: FDA launches mobile-friendly database with information on life-saving HIV drugs10/30/2019
			Label updates to efavirenz containing products10/4/2019
			DESCOVY for PrEP: Post-marketing commitment (PMC)



Access older postings to the FDA/HIV e-mail list*

*FDA recently made updates to part of their email based communication. You can still view the updates by going to Internet Archive Wayback Machine for FDA.gov. The For Patients section of FDA.GOV was backed up last on July 29, 2017. This non-profit Internet Archive has archived some (but not all) of FDA.gov pages and files since 1996.

                                                                                  Content current as of:
      03/11/2021
              
              
Regulated Product(s)
		 Drugs
			  			     			  						              
			
			
			
			
						  HIV/AIDS DrugsHealth Topic(s)
			  HIV/AIDSHuman Immunodeficiency Virus (HIV)

          
                        About HIV and the Center for Drug Evaluation and Research's role
          What's New at CDER in HIV/AIDS


                        HIV Treatment
 SUBSCRIBE
                      Get regular FDA email updates delivered on this topic to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop